Q3 US Device Approvals Snapshot: Apps Up, Original PMAs Down
Executive Summary
Mobile apps made major headway into the world of US FDA regulation in the third quarter, with de novo go-aheads for two Apple Watch heart-rhythm apps and the first FDA approval of a smartphone app to support contraception. Meanwhile, original PMA-approval volumes continue to lag in 2018. Here's an infographic to spotlight US device approval trends during the third quarter, July through September.
You may also be interested in...
Global Device Approvals, Weekly Snapshot: PMA Drought Continues
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. A electrical stimulator for GI disease is among devices that made the list this week. Also, a drought in original PMAs and panel-track supplements in the US.
FDA's Speedy Apple Watch De Novos Raise Questions For Industry
The recent US FDA de novo approvals for heart-rhythm analysis software on Apple's latest Apple Watch, which took about 30 days from submission to a decision that aligned with Apple's high-profile launch event, raised eyebrows in the medtech industry. Some in industry are concerned that the tech giant received preferential treatment over smaller companies, setting a bad precedent. But some say it could be a positive sign for the digital health industry at large.
Q&A: What Do FDA’s Recent Medical App Approvals Mean For Industry?
Marc Scheineson, a former US FDA associate commissioner who now heads Alston & Bird’s food and drug law practice, offered insight into the agency's latest moves in regulating medical apps and what industry should watch for.